

2 April 2024

Osteopore issues Replacement Prospectus for Entitlement Offer

Singapore-founded regenerative medicine company **Osteopore Limited (ASX:OSX or the Company)** – a global leader in 3D-printed biomimetic and bioresorbable implants – has issued a replacement prospectus dated today to replace the prospectus dated 13 March 2024 relating to the 10-for-1 Renounceable Pro-Rata Entitlement Offer at A\$0.029 per share to raise ~A\$3,000,000 (before costs) (**Entitlement Offer**) (**Replacement Prospectus**).

Indicative Timetable

The Entitlement Offer – as defined in the Replacement Prospectus – will be undertaken in accordance with the indicative timetable below:

Event	Date
Original Prospectus Lodgement Date	13 March 2024
Announcement of Prospectus & Appendix 3B with ASX	13 March 2024
“Ex” date	15 March 2024
Rights start trading	15 March 2024
Record date to determine Entitlements	18 March 2024
Prospectus with Application Form dispatched	19 March 2024
Entitlement Offer opens for receipt of Applications	19 March 2024
Rights trading ends at close of trading	22 March 2024
Securities quoted on a deferred settlement basis	25 March 2024



Last day to extend the Closing Date (before noon AEDT)	26 March 2024
Replacement Prospectus Lodgement Date	2 April 2024
Closing Date as at 5.00pm	2 May 2024
Announcement of results of the Entitlement Offer	6 May 2024
Issue of New Shares and New Options and lodgement of Appendix 2A with ASX applying for quotation of New Shares	8 May 2024
Quotation of New Shares issued under the Offer	9 May 2024

*Dates – other than the date of the Prospectus and the Prospectus Lodgement Date with ASIC and ASX – are indicative only. The Directors may decide to extend the Closing Date of the Entitlement Offer by notifying ASX – a minimum of three business days – before the Closing Date. Subsequently, the date that the Securities are expected to commence trading may vary.

Replacement Prospectus

Details of the Entitlement Offer are contained within the Replacement Prospectus. A copy of the Replacement Prospectus will be e-lodged to the ASX via ASX Online together with this Announcement. The Replacement Prospectus is also available on the Company's website at www.osteopore.com/investors. The Directors of Osteopore encourage shareholders to read the Replacement Prospectus carefully and to seek independent advice from your financial adviser.

ENDS

This announcement dated 2 April 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr. Yujing Lim
 CEO & CTO
 Osteopore Limited
 E: lim_yujing@osteopore.com

Isaac Stewart
 Media & Investor Relations
 Cannings Purple
 E: istewart@canningspurple.com.au



About Osteopore Limited

Osteopore Limited is a Singapore-founded regenerative medicine company and a global leader in 3D-printed biomimetic and bioresorbable implants. The Company seeks to commercialise products that stimulate natural bone healing across multiple segments.

Osteopore creates patented scaffolds using 3D-printed biomimetic and bioresorbable materials to guide and nurture bone-forming cells.

Through our proprietary manufacturing process – which uses a naturally dissolving polymer – our patented scaffolds enable bone tissue growth, significantly reducing the post-surgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

